These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33804790)

  • 1. The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature.
    Berman M; Ben-Ami R; Berliner S; Anouk M; Kaufman I; Broyde A; Borok S; Elkayam O
    Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33804790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.
    Gale S; Trinh H; Tuckwell K; Collinson N; Stone JH; Sarsour K; Pei J; Best J; Birchwood C; Mohan SV
    Rheumatol Ther; 2019 Mar; 6(1):77-88. PubMed ID: 30707391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab - An attention may be required.
    Berman M; Berliner S; Bashouti N; Elkayam O; Ziv-Baran T
    Heliyon; 2023 Jun; 9(6):e16665. PubMed ID: 37292345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
    Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AA amyloidosis treated with tocilizumab: case series and updated literature review.
    Courties A; Grateau G; Philippe P; Flipo RM; Astudillo L; Aubry-Rozier B; Fabreguet I; Fahd W; Fain O; Guggenbuhl P; Hachulla E; Papo T; Richez C; Sibilia J; Morel J; Berenbaum F; Sellam J;
    Amyloid; 2015; 22(2):84-92. PubMed ID: 25585627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erysipelas without fever or biologic inflammation during tocilizumab therapy].
    Yéléhé-Okouma M; Henry J; Petitpain N; Schmutz JL; Gillet P
    Ann Dermatol Venereol; 2017; 144(6-7):434-437. PubMed ID: 28396064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.
    Evans J; Steel L; Borg F; Dasgupta B
    RMD Open; 2016; 2(1):e000137. PubMed ID: 26819753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
    Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review.
    Del Giorno R; Iodice A; Mangas C; Gabutti L
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19841796. PubMed ID: 31019572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Prieto-Peña D; Atienza-Mateo B; Patiño E; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Loricera J; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):112-119. PubMed ID: 32441643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
    Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
    Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study.
    Momohara S; Hashimoto J; Tsuboi H; Miyahara H; Nakagawa N; Kaneko A; Kondo N; Matsuno H; Wada T; Nonaka T; Kanbe K; Takagi H; Murasawa A; Matsubara T; Suguro T
    Mod Rheumatol; 2013 May; 23(3):440-9. PubMed ID: 22684398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients.
    Loricera J; Castañeda S; Moriano C; Narváez J; Aldasoro V; Maiz O; Melero R; Villa I; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sánchez-Martín J; Sánchez-Bilbao L; Calderón-Goercke M; Casado A; Hernández JL; González-Gay MA; Blanco R
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221113747. PubMed ID: 35898567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous Spinal Epidural Hematoma During Simultaneous Tocilizumab and Warfarin Use in a Patient With Rheumatoid Arthritis: Is There a Drug Interaction Between Tocilizumab and Oral Anticoagulants?
    Güneş S; Gök H; Ataman Ş; Kutlay Ş
    Arch Rheumatol; 2020 Dec; 35(4):614-617. PubMed ID: 33758819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical characteristics and severity of community-acquired pneumonia between patients with rheumatoid arthritis treated with tocilizumab and those treated with TNF inhibitor.
    Nagai Y; Yokogawa N; Shimada K; Sugii S
    Mod Rheumatol; 2019 Sep; 29(5):782-787. PubMed ID: 30132358
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
    Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.